The Motley Fool
22 Aug 2026, 21:22 UTC · 1h ago
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
22 Aug 2026, 21:22 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Analysts maintain a strongly bullish outlook on Cytokinetics (CYTK), with 91% rating it a 'buy' and a median price target of $107.50. — High analyst conviction and a significant implied upside of nearly 40% provide strong fundamental support for the stock price.
+0.60CEO Robert I. Blum retains a substantial ownership stake of over 380,000 shares in Cytokinetics. — Large remaining equity ownership indicates that the executive's interests remain aligned with long-term shareholder value.
+0.20Cytokinetics CEO Robert I. Blum sold 7,500 shares on August 10, 2026, after exercising options at a strike price of $10.60. — While insider selling can be a red flag, this specific transaction is characterized as routine profit-taking following a 100% price increase.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
Despite an insider sale, the company has strong commercial traction, high analyst buy ratings, and a significantly higher median price target than the current price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
